CutisPharma Obtains Patent for Suppository Compounding.CutisPharma, Inc. (Woburn, MA) received approval from the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property for its patent (United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories suppositories, n.pl solid capsules made of materials that melt at body temperature and are used to deliver medicinal substances into the rectum. . "By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CutisPharma, Inc. "Our container (suppository suppository /sup·pos·i·to·ry/ (su-poz´i-tor?e) an easily fusible medicated mass to be introduced into a body orifice, as the rectum, urethra, or vagina. sup·pos·i·to·ry n. mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added. Currently CutisPharma has FIRST Progesterone progesterone (prōjĕs`tərōn'), female sex hormone that induces secretory changes in the lining of the uterus essential for successful implantation of a fertilized egg. Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST - Progesterone VGS VGS Videregående Skole (Norwegian school) VGS Virtual Game Station VGS Voodoo Glow Skulls (Ska band) VGS Video Game System VGS Volunteer Gliding School VGS Voltage Gate to Source VGS Velocity Gate Stealer 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid boric acid, any one of the three chemical compounds, orthoboric (or boracic) acid, metaboric acid, and tetraboric (or pyroboric) acid; the term often refers simply to orthoboric acid. The acids may be thought of as hydrates of boric oxide, B2O3. , Morphine morphine, principal derivative of opium, which is the juice in the unripe seed pods of the opium poppy, Papaver somniferum. It was first isolated from opium in 1803 by the German pharmacist F. W. A. , and others. CutisPharma estimates that over 1.5 million progesterone suppository prescriptions are written in the United States annually, representing a potential of nearly $100 million at the retail level. The Kit allows a pharmacy an easy entry into this market. The company is experiencing a steady conversion from the conventional way to the FIRST - way. FIRST products save dispensing time, are easy to use, and can be compounded by the pharmacist while the patient waits increasing customer satisfaction. Using FIRST VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared by the traditional method using a metal suppository mold or polystyrene shells. CutisPharma is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two United States patents have been issued to the company with several additional patents pending. CutisPharma, Inc. +1-781-935-8141 www.cutispharma.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion